360 related articles for article (PubMed ID: 29976748)
1. CD16
Williams BA; Wang XH; Leyton JV; Maghera S; Deif B; Reilly RM; Minden MD; Keating A
Haematologica; 2018 Oct; 103(10):1720-1729. PubMed ID: 29976748
[TBL] [Abstract][Full Text] [Related]
2. Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC.
Busfield SJ; Biondo M; Wong M; Ramshaw HS; Lee EM; Ghosh S; Braley H; Panousis C; Roberts AW; He SZ; Thomas D; Fabri L; Vairo G; Lock RB; Lopez AF; Nash AD
Leukemia; 2014 Nov; 28(11):2213-21. PubMed ID: 24705479
[TBL] [Abstract][Full Text] [Related]
3. Auger electron radioimmunotherapeutic agent specific for the CD123+/CD131- phenotype of the leukemia stem cell population.
Leyton JV; Hu M; Gao C; Turner PV; Dick JE; Minden M; Reilly RM
J Nucl Med; 2011 Sep; 52(9):1465-73. PubMed ID: 21816968
[TBL] [Abstract][Full Text] [Related]
4. Development of a novel fully-human anti-CD123 antibody to target acute myeloid leukemia.
Hutmacher C; Volta L; Rinaldi F; Murer P; Myburgh R; Manz MG; Neri D
Leuk Res; 2019 Sep; 84():106178. PubMed ID: 31326578
[TBL] [Abstract][Full Text] [Related]
5. Improved Activity against Acute Myeloid Leukemia with Chimeric Antigen Receptor (CAR)-NK-92 Cells Designed to Target CD123.
Morgan MA; Kloos A; Lenz D; Kattre N; Nowak J; Bentele M; Keisker M; Dahlke J; Zimmermann K; Sauer M; Heuser M; Schambach A
Viruses; 2021 Jul; 13(7):. PubMed ID: 34372571
[TBL] [Abstract][Full Text] [Related]
6. Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha chain, eliminates human acute myeloid leukemic stem cells.
Jin L; Lee EM; Ramshaw HS; Busfield SJ; Peoppl AG; Wilkinson L; Guthridge MA; Thomas D; Barry EF; Boyd A; Gearing DP; Vairo G; Lopez AF; Dick JE; Lock RB
Cell Stem Cell; 2009 Jul; 5(1):31-42. PubMed ID: 19570512
[TBL] [Abstract][Full Text] [Related]
7. A trispecific killer engager molecule against CLEC12A effectively induces NK-cell mediated killing of AML cells.
Arvindam US; van Hauten PMM; Schirm D; Schaap N; Hobo W; Blazar BR; Vallera DA; Dolstra H; Felices M; Miller JS
Leukemia; 2021 Jun; 35(6):1586-1596. PubMed ID: 33097838
[TBL] [Abstract][Full Text] [Related]
8. Humanized anti-CD123 antibody facilitates NK cell antibody-dependent cell-mediated cytotoxicity (ADCC) of Hodgkin lymphoma targets via ARF6/PLD-1.
Ernst D; Williams BA; Wang XH; Yoon N; Kim KP; Chiu J; Luo ZJ; Hermans KG; Krueger J; Keating A
Blood Cancer J; 2019 Jan; 9(2):6. PubMed ID: 30647406
[TBL] [Abstract][Full Text] [Related]
9. Optimization of Human NK Cell Manufacturing: Fully Automated Separation, Improved Ex Vivo Expansion Using IL-21 with Autologous Feeder Cells, and Generation of Anti-CD123-CAR-Expressing Effector Cells.
Klöß S; Oberschmidt O; Morgan M; Dahlke J; Arseniev L; Huppert V; Granzin M; Gardlowski T; Matthies N; Soltenborn S; Schambach A; Koehl U
Hum Gene Ther; 2017 Oct; 28(10):897-913. PubMed ID: 28810809
[TBL] [Abstract][Full Text] [Related]
10. Gene-modified NK-92MI cells expressing a chimeric CD16-BB-ζ or CD64-BB-ζ receptor exhibit enhanced cancer-killing ability in combination with therapeutic antibody.
Chen Y; You F; Jiang L; Li J; Zhu X; Bao Y; Sun X; Tang X; Meng H; An G; Zhang B; Yang L
Oncotarget; 2017 Jun; 8(23):37128-37139. PubMed ID: 28415754
[TBL] [Abstract][Full Text] [Related]
11. Antileukemia Efficacy and Mechanisms of Action of SL-101, a Novel Anti-CD123 Antibody Conjugate, in Acute Myeloid Leukemia.
Han L; Jorgensen JL; Brooks C; Shi C; Zhang Q; Nogueras González GM; Cavazos A; Pan R; Mu H; Wang SA; Zhou J; Ai-Atrash G; Ciurea SO; Rettig M; DiPersio JF; Cortes J; Huang X; Kantarjian HM; Andreeff M; Ravandi F; Konopleva M
Clin Cancer Res; 2017 Jul; 23(13):3385-3395. PubMed ID: 28096272
[No Abstract] [Full Text] [Related]
12. AntiCD3Fv fused to human interleukin-3 deletion variant redirected T cells against human acute myeloid leukemic stem cells.
Fan D; Li Z; Zhang X; Yang Y; Yuan X; Zhang X; Yang M; Zhang Y; Xiong D
J Hematol Oncol; 2015 Feb; 8():18. PubMed ID: 25879549
[TBL] [Abstract][Full Text] [Related]
13. Engineering CAR-NK cells to secrete IL-15 sustains their anti-AML functionality but is associated with systemic toxicities.
Christodoulou I; Ho WJ; Marple A; Ravich JW; Tam A; Rahnama R; Fearnow A; Rietberg C; Yanik S; Solomou EE; Varadhan R; Koldobskiy MA; Bonifant CL
J Immunother Cancer; 2021 Dec; 9(12):. PubMed ID: 34896980
[TBL] [Abstract][Full Text] [Related]
14. A Phase 1 study of the safety, pharmacokinetics and anti-leukemic activity of the anti-CD123 monoclonal antibody CSL360 in relapsed, refractory or high-risk acute myeloid leukemia.
He SZ; Busfield S; Ritchie DS; Hertzberg MS; Durrant S; Lewis ID; Marlton P; McLachlan AJ; Kerridge I; Bradstock KF; Kennedy G; Boyd AW; Yeadon TM; Lopez AF; Ramshaw HS; Iland H; Bamford S; Barnden M; DeWitte M; Basser R; Roberts AW
Leuk Lymphoma; 2015 May; 56(5):1406-15. PubMed ID: 25248882
[TBL] [Abstract][Full Text] [Related]
15. Targeting CD157 in AML using a novel, Fc-engineered antibody construct.
Krupka C; Lichtenegger FS; Köhnke T; Bögeholz J; Bücklein V; Roiss M; Altmann T; Do TU; Dusek R; Wilson K; Bisht A; Terrett J; Aud D; Pombo-Villar E; Rohlff C; Hiddemann W; Subklewe M
Oncotarget; 2017 May; 8(22):35707-35717. PubMed ID: 28415689
[TBL] [Abstract][Full Text] [Related]
16. Cytotoxicity Assessment and Apoptosis-related Gene Profiling of Antibody Treated Acute Myeloid Leukemia (AML) and Acute Lymphocytic Leukemia (ALL) Cancerous Cell Lines.
Habibi-Anbouhi M; Kafi Z; Ghazizadeh L; Kharazi S; Behdani M; Faraji F; Shokrgozar MA
Iran J Allergy Asthma Immunol; 2019 Oct; 18(6):679-687. PubMed ID: 32245312
[TBL] [Abstract][Full Text] [Related]
17. T cells expressing CD123-specific chimeric antigen receptors exhibit specific cytolytic effector functions and antitumor effects against human acute myeloid leukemia.
Mardiros A; Dos Santos C; McDonald T; Brown CE; Wang X; Budde LE; Hoffman L; Aguilar B; Chang WC; Bretzlaff W; Chang B; Jonnalagadda M; Starr R; Ostberg JR; Jensen MC; Bhatia R; Forman SJ
Blood; 2013 Oct; 122(18):3138-48. PubMed ID: 24030378
[TBL] [Abstract][Full Text] [Related]
18. The interleukin-3 receptor CD123 targeted SL-401 mediates potent cytotoxic activity against CD34
Mani R; Goswami S; Gopalakrishnan B; Ramaswamy R; Wasmuth R; Tran M; Mo X; Gordon A; Bucci D; Lucas DM; Mims A; Brooks C; Dorrance A; Walker A; Blum W; Byrd JC; Lozanski G; Vasu S; Muthusamy N
Haematologica; 2018 Aug; 103(8):1288-1297. PubMed ID: 29773600
[TBL] [Abstract][Full Text] [Related]
19. [Construction of a new anti-CD123 chimeric antigen receptor T cells and effect of anti-acute myeloid leukemia].
Wang ZZ; Lu Y; Xu YX; Xing HY; Tang KJ; Tian Z; Rao Q; Wang M; Xiong DS; Wang JX
Zhonghua Xue Ye Xue Za Zhi; 2020 Mar; 41(3):192-197. PubMed ID: 32311887
[No Abstract] [Full Text] [Related]
20. Development of Highly Optimized Antibody-Drug Conjugates against CD33 and CD123 for Acute Myeloid Leukemia.
Han YC; Kahler J; Piché-Nicholas N; Hu W; Thibault S; Jiang F; Leal M; Katragadda M; Maderna A; Dushin R; Prashad N; Charati MB; Clark T; Tumey LN; Tan X; Giannakou A; Rosfjord E; Gerber HP; Tchistiakova L; Loganzo F; O'Donnell CJ; Sapra P
Clin Cancer Res; 2021 Jan; 27(2):622-631. PubMed ID: 33148666
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
